ZFP36L1 and acute myeloid leukemia: In summary, our results demonstrated that ZFP36L1-mediated post-transcriptional control of CDK6 expression through binding to its 3′UTR implicates a novel regulatory circuit in monocyte/macrophage differentiation, which may also provide a therapeutic target for AML patients with abnormal expression of ZFP36L1 and CDK6.